✦ LIBER ✦

1675 LONG-TERM SURVIVAL OUTCOMES WITH INTRAVESICAL DOCETAXEL IN THE MANAGEMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) REFRACTORY TO BCG THERAPY

✍ Scribed by Barlow, LaMont; McKiernan, James; Benson, Mitchell

Book ID: 122871902
Publisher: Lippincott Williams and Wilkins
Year: 2012
Tongue: English
Weight: 46 KB
Volume: 187
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2012.02.1533

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term Clinical Outcomes of a Phase I

Long-term Clinical Outcomes of a Phase I Trial of Intravesical Docetaxel in the Management of Non–muscle-invasive Bladder Cancer Refractory to Standard Intravesical Therapy

✍ Melissa A. Laudano; Lamont J. Barlow; Alana M. Murphy; Daniel P. Petrylak; Manis 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 194 KB

The novel use of intravesical docetaxel

The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience

✍ LaMont J. Barlow; James M. McKiernan; Mitchell C. Benson 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 237 KB

LONG TERM CLINICAL OUTCOME OF A PHASE I

LONG TERM CLINICAL OUTCOME OF A PHASE I TRIAL OF INTRAVESICAL DOCETAXEL IN THE MANAGEMENT OF SUPERFICIAL BLADDER CANCER REFRACTORY TO STANDARD INTRAVESICAL THERAPY

✍ Laudano, Melissa A; Murphy, Alana M; Petrylak, Daniel P; Desai, Manisha; Benson, 📂 Article 📅 2008 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 137 KB

A single-institution experience with ind

A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy

✍ LaMont Barlow; James McKiernan; Ihor Sawczuk; Mitchell Benson 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB